While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY NHI-Market Price Gap Narrowed, but Chuikyo Payer Reps Say Normal Revision Possible
December 5, 2022
-
REGULATORY Average NHI-Market Price Gap for 2023 Off-Year Revision at 7.0%: MHLW
December 2, 2022
-
BUSINESS AstraZeneca Japan Set to Buttress Respiratory Business with Tezspire Debut
December 2, 2022
-
BUSINESS Ultragenyx to Ramp Up Ultra-Orphan Drug Development, Bolster Hiring in Japan
December 1, 2022
-
BUSINESS Eisai Says 2 Trial Deaths Not Attributed to Lecanemab, No Change in Submission Plan
December 1, 2022
-
REGULATORY MOF Panel Presses for Full Annual Price Cuts, Rethink of COVID-Related Government Purchase
November 30, 2022
-
BUSINESS No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
November 30, 2022
-
REGULATORY Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
November 29, 2022
-
COMMENTARY Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
-
BUSINESS Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
-
REGULATORY Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
-
COMMENTARY Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
November 22, 2022
-
ACADEMIA Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
November 21, 2022
-
BUSINESS Big 3 Generic Firms Struggle in H1; Nichi-Iko Logs Excess Debt as Profits Tank for Rivals
November 18, 2022
-
BUSINESS Merck R&D Chief Confident on Expanding Pipeline towards Keytruda Patent Cliff and Beyond
November 17, 2022
-
BUSINESS Top 4 Wholesalers on Recovery Trend, Operating Profit Up 69.1% in April-September
November 16, 2022
-
BUSINESS Nichi-Iko to Be Delisted, Seeks Turnaround under Medipal-JWP Joint Firm; President to Bow Out
November 15, 2022
-
REGULATORY Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
November 15, 2022
-
BUSINESS Asian Regulatory Harmonization Underutilized by Japan Drug Makers, Priorities on Western Markets
November 14, 2022
-
REGULATORY Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
November 14, 2022
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…